Gene therapy for hemophilia

Journal of Gene Medicine

Volumn 3, Issue 1, 2001, Pages 3-20

  Chuah, Marinee K L ^a   Collen, Desire ^a   VandenDriessche, Thierry ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Coagulation; Factor IX; Factor VIII; Gene therapy; Hemophilia

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

ANIMAL; CLINICAL TRIAL; DOG; GENE THERAPY; GENE VECTOR; HEMOPHILIA A; HEMOPHILIA B; HUMAN; REVIEW;

ANIMALS; CLINICAL TRIALS; DOGS; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA A; HEMOPHILIA B; HUMANS;

EID: 0035221248     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-2254(200101/02)3:1<3::AID-JGM167>3.0.CO;2-H     Document Type: Review

References (180)

1. Kaufman RJ. Advances toward gene therapy for hemophilia at the millennium. Hum Gene Ther 1999; 10: 2091-2107.
2. Peerlinck K, Arnout J, Di Giambattista M, et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-86.
3. Lozier JN, Brinkhous KM. Gene therapy and the hemophilias [see Comments]. JAMA 1994; 271: 47-51.
4. Morgan RA, Anderson WF. Human gene therapy. Annu Rev Biochem 1993; 62: 191-217.
5. Hoeben RC. Gene therapy for the haemophilias: current status. Biological 1995; 23: 27-29.
6. Eisensmith RC, Woo SL. Viral vector-mediated gene therapy for hemophilia B. Thromb Haemost 1997; 78: 24-30.
7. Connelly S, Kaleko M. Gene therapy for hemophilia A. Thromb Haemost 1997; 78: 31-36.
8. Kurachi K, Yao SN, Furukawa M, Kurachi S. Deficiencies in factors IX and VIII: what is now known. Hosp Pract (Off Ed) 1992; 27: 41-51.
9. Fallaux FJ, Hoeben RC. Gene therapy for the hemophilias. Curr Opin Hematol 1996; 3: 385-389.
10. Thompson AR. Status of gene transfer for hemophilia A and B. Thromb Haemost 1991; 66: 119-122.
11. Chuah MK, Collen D, VandenDriessche T. Gene therapy for hemophilia: hopes and hurdles. Crit Rev Oncol Hematol 1998; 28: 153-171.
12. White IIGC, Roberts HR. Gene therapy for hemophilia: a step closer to reality. Mol Ther 2000; 1: 207-208.
13. Kay MA, High K. Gene therapy for the hemophilias [comment]. Proc Natl Acad Sci U S A 1999; 96: 9973-9975.
14. Walter J, High KA. Gene therapy for the hemophilias. Adv Vet Med 1997; 40: 119-134.
15. St Louis D, Verma IM. An alternative approach to somatic cell gene therapy. Proc Natl Acad Sci U S A 1988; 85: 3150-3154.
16. Axelrod JH, Read MS, Brinkhous KM, Verma IM. Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs. Proc Natl Acad Sci U S A 1990; 87: 5173-5177.
17. Hoeben RC, van der Jagt RC, Schoute F, et al. Expression of functional factor VIII in primary human skin fibroblasts after retrovirus-mediated gene transfer. J Biol Chem 1990; 265: 7318-7323.
18. Page SM, Brownlee GG. An ex vivo keratinocyte model for gene therapy of hemophilia B. J Invest Dermatol 1997; 109: 139-145.
19. Fenjves ES, Yao SN, Kurachi K, Taichman LB. Loss of expression of a retrovirus-transduced gene in human keratinocytes. J Invest Dermatol 1996; 106: 576-578.
20. Fakharzadeh SS, Zhang Y, Sarkar R, Kazazian Jr HH. Correction of the coagulation defect in hemophilia A mice through factor VIII expression in skin. Blood 2000; 95: 2799-2805.
21. Chuah MK, VandenDriessche T, Morgan RA. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Hum Gene Ther 1995; 6: 1363-1377.
22. Dwarki VJ, Belloni P, Nijjar T, et al. Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci U S A 1995; 92: 1023-1027.
23. Yao SN, Wilson JM, Nabel EG, et al. Expression of human factor IX in rat capillary endothelial cells: toward somatic gene therapy for hemophilia B. Proc Natl Acad Sci U S A 1991; 88: 8101-8105.
24. Hortelano G, Al Hendy A, Ofosu FA, Chang PL. Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. Blood 1996; 87: 5095-5103.
25. Yao SN, Kurachi K. Expression of human factor IX in mice after injection of genetically modified myoblasts. Proc Natl Acad Sci U S A 1992; 89: 3357-3361.
26. Yao SN, Smith KJ, Kurachi K. Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice. Gene Ther 1994; 1: 99-107.
27. Dai Y, Roman M, Naviaux RK, Verma IM. Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci U S A 1992; 89: 10892-10895.
28. Baru M, Sha'anani J, Nur I. Retroviral-mediated in vivo gene transfer into muscle cells and synthesis of human factor IX in mice. Intervirology 1995; 38: 356-360.
29. Hao QL, Malik P, Salazar R, et al. Expression of biologically active human factor IX in human hematopoietic cells after retroviral vector-mediated gene transduction. Hum Gene Ther 1995; 6: 873-880.
30. Hoeben RC, Einerhand MP, Briet E, et al. Toward gene therapy in haemophilia A: retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb Haemost 1992; 67: 341-345.
31. Hurwitz DR, Kirchgesser M, Merrill W, et al. Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells. Hum Gene Ther 1997; 8: 137-156.
32. Do H, Healey JF, Waller EK, Lollar P. Expression of factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem 1999; 274: 19587-19592.
33. Wang L, Zoppe M, Hackeng TM, et al. factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A 1997; 94: 11563-11566.
34. Bi L, Lawler AM, Antonarakis SE, et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A [Letter]. Nat Genet 1995; 10: 119-121.
35. Bi L, Sarkar R, Naas T, et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 3446-3450.
36. Kundu RK, Sangiorgi F, Wu LY, et al. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. Blood 1998; 92: 168-174.
37. Giles AR, Tinlin S, Hoogendoorn H, et al. Development of factor VIII: C antibodies in dogs with hemophilia A (factor VIII: C deficiency). Blood 1984; 63: 451-456.
38. Evans JP, Brinkhous KM, Brayer GD, et al. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci U S A 1989; 86: 10095-10099.
39. Zatloukal K, Cotten M, Berger M, et al. In vivo production of human factor VII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery. Proc Natl Acad Sci U S A 1994; 91: 5148-5152.
40. Lozier JN, Thompson AR, Hu PC, et al. Efficient transfection of primary cells in a canine hemophilia B model using adenovirus-polylysine-DNA complexes. Hum Gene Ther 1994; 5: 313-322.
41. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326-330.
42. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-337.
43. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-347.
44. Toole JJ, Pittman DD, Orr EC, et al. large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci U S A 1986; 83: 5939-5942.
45. Berntorp E. Second generation, B-domain deleted recombinant factor VIII. Thromb Haemost 1997; 78: 256-260.
46. Israel DI, Kaufman RJ. Retroviral-mediated transfer and amplification of a functional human factor VIII gene. Blood 1990; 75: 1074-1080.
47. Lynch CM, Israel DI, Kaufman RJ, Miller AD. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993; 4: 259-272.
48. Hoeben RC, Fallaux FJ, Cramer SJ, et al. Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood 1995; 85: 2447-2454.
49. Fallaux FJ, Hoeben RC, Cramer SJ, et al. The human clotting factor VIII cDNA contains an autonomously replicating sequence consensus- and matrix attachment region-like sequence that binds a nuclear factor, represses heterologous gene expression, and mediates the transcriptional effects of sodium butyrate. Mol Cell Biol 1996; 16: 4264-4272.
50. Ill CR, Yang CQ, Bidlingmaier SM, et al. Optimization of the human factor VIII complementary DNA expression plasmid for gene therapy of hemophilia A. Blood Coagul Fibrinolysis 1997; 8 (Suppl. 2): S23-S30.
51. Koeberl DD, Halbert CL, Krumm A, Miller AD. Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation. Hum Gene Ther 1995; 6: 469-479.
52. Pittman DD, Kaufman RJ. Structure-function relationships of factor VIII elucidated through recombinant DNA technology. Thromb Haemost 1989; 61: 161-165.
53. Dorner AJ, Kaufman RJ. The levels of endoplasmic reticulum proteins and ATP affect folding and secretion of selective proteins. Biologicals 1994; 22: 103-112.
54. Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352-6362.
55. Miller AD. Retroviral vectors. Curr Top Microbiol Immunol 1992; 158: 1-24.
56. Miller AD, Miller DG, Garcia JV, Lynch CM. Use of retroviral vectors for gene transfer and expression. Methods Enzymol 1993; 217: 581-599.
57. Anderson WF. Human gene therapy. Nature 1998; 392: 25-30.
58. Cornetta K, Morgan RA, Anderson WF. Safety issues related to retroviral-mediated gene transfer in humans. Hum Gene Ther 1991; 2: 5-14.
59. Anderson WF, McGarrity GJ, Moen RC. Report to the NIH Recombinant DNA Advisory Committee on murine replication-competent retrovirus (RCR) assays (February 17, 1993). Hum Gene Ther 1993; 4: 311-321.
60. Donahue RE, Kessler SW, Bodine D, et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 1992; 176: 1125-1135.
61. Hamer DH, Leder P. Splicing and the formation of stable RNA. Cell 1979; 18: 1299-1302.
62. Palmiter RD, Sandgren EP, Avarbock MR, et al. Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci U S A 1991; 88: 478-482.
63. Krall W, Kohn DB. Expression levels by retroviral vectors based upon the N2 and the MFG backbones [Letter]. Gene Ther 1996; 3.
64. Hoeben RC, Fallaux FJ, Van Tilburg NH, et al. Toward gene therapy for hemophilia A: long-term persistence of factor VIII-secreting fibroblasts after transplantation into immunodeficient mice. Hum Gene Ther 1993; 4: 179-186.
65. Evans GL, Morgan RA. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci U S A 1998; 95: 5734-5739.
66. Drize NJ, Surin VL, Gan OI, et al. Gene therapy model for stromal precursor cells of hematopoietic microenvironment. Leukemia 1992; 6 Suppl 3: 174S-175S.
67. Nolta JA, Hanley MB, Kohn DB. Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human interleukin-3: analysis of gene transduction of long-lived progenitors. Blood 1994; 83: 3041-3051.
68. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71-74.
69. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
70. Li KJ, Dilber MS, Abedi MR, et al. Retroviral-mediated gene transfer into human bone marrow stromal cells: studies of efficiency and in vivo survival in SCID mice. Eur J Haematol 1995; 55: 302-306.
71. Chuah MK, Brems H, Vanslembrouck V, et al. Bone marrow stromal cells as targets for gene therapy of hemophilia A. Hum Gene Ther 1998; 9: 353-365.
72. Chuah MK, Van Damme A, Zwinnen H, et al. Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. Hum Gene Ther 2000; 11: 729-738.
73. Kay MA, Rothenberg S, Landen CN, et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs [see Comments]. Science 1993; 262: 117-119.
74. Rettinger SD, Kennedy SC, Wu X, et al. Liver-directed gene therapy: quantitative evaluation of promoter elements by using in vivo retroviral transduction. Proc Natl Acad Sci U S A 1994; 91: 1460-1464.
75. Bosch A, McCray JrPB, Chang SM, et al. Proliferation induced by keratinocyte growth factor enhances in vivo retroviral-mediated gene transfer to mouse hepatocytes. J Clin Invest 1996; 98: 2683-2687.
76. Patijn GA, Lieber A, Schowalter DB, et al. Hepatocyte growth factor induces hepatocyte proliferation in vivo and allows for efficient retroviral-mediated gene transfer in mice. Hepatology 1998; 28: 707-716.
77. VandenDriessche T, Vanslembrouck V, Goovaerts I, et al. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice [see Comments]. Proc Natl Acad Sci U S A 1999; 96: 10379-10384.
78. Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/ vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A 1996; 93: 11400-11406.
79. Takeuchi Y, Porter CD, Strahan KM, et al. Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature 1996; 379: 85-88.
80. Cosset FL, Takeuchi Y, Battini JL, et al. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
81. Alison M. Liver stem cells: a two compartment system. Curr Opin Cell Biol 1998; 10: 710-715.
82. Kay MA, Fausto N. Liver regeneration: prospects for therapy based on new technologies. Mol Med Today 1997; 3: 108-115.
83. Tian YW, Smith PG, Yeoh GC. The oval-shaped cell as a candidate for a liver stem cell in embryonic, neonatal and precancerous liver: identification based on morphology and immunohistochemical staining for albumin and pyruvate kinase isoenzyme expression. Histochem Cell Biol 1997; 107: 243-250.
84. Pittman DD, Alderman EM, Tomkinson KN, et al. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993; 81: 2925-2935.
85. Greengard JS, Jolly DJ. Animal testing of retroviral-mediated gene therapy for factor VIII deficiency. Thromb Haemost 1999; 82: 555-561.
86. Naldini L, Blomer U, Gage FH, et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 1996; 93: 11382-11388.
87. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector [see Comments]. Science 1996; 272: 263-267.
88. Blomer U, Naldini L, Kafri T, et al. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 1997; 71: 6641-6649.
89. Zufferey R, Nagy D, Mandel RJ, et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
90. Park F, Ohashi K, Chiu W, et al. Efficient lentiviral transduction of liver requires cell cycling in vivo. Nat Genet 2000; 24: 49-52.
91. Park F, Ohashi K, Kay MA. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 2000; 96: 1173-1176.
92. Kafri T, van Praag H, Ouyang L, et al. packaging cell line for lentivirus vectors. J Virol 1999; 73: 576-584.
93. Dull T, Zufferey R, Kelly M, et al. third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
94. Kafri T, Blomer U, Peterson DA, et al. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17: 314-317.
95. Chinnasamy D, Chinnasamy N, Enriquez MJ, et al. Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins. Blood 2000; 96: 1309-1316.
96. Follenzi A, Ailles LE, Bakovic S, et al. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25: 217-222.
97. Pasture L, Morral N, Zhou H, et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999; 10: 1773-1781.
98. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 1988; 6: 616-629.
99. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2: 545-550.
100. Connelly S, Mount J, Mauser A, et al. Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood 1996; 88: 3846-3853.
101. Lozier JN, Metzger ME, Donahue RE, Morgan RA. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity [see Comments]. Blood 1999; 94: 3968-3975.
102. Yeh P, Dedieu JF, Orsini C, et al. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 1996; 70: 559-565.
103. Armentano D, Sookdeo CC, Hehir KM, et al. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum Gene Ther 1995; 6: 1343-1353.
104. Wang Q, Jia XC, Finer MH. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther 1995; 2: 775-783.
105. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996; 70: 8934-8943.
106. Connelly S, Smith TA, Dhir G, et al. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther 1995; 6: 185-193.
107. Connelly S, Gardner JM, McClelland A, Kaleko M. High-level tissue-specific expression of functional human factor VIII in mice. Hum Gene Ther 1996; 7: 183-195.
108. Connelly S, Gardner JM, Lyons RM, et al. Sustained expression of therapeutic levels of human factor VIII in mice. Blood 1996; 87: 4671-4677.
109. Connelly S, Andrews JL, Gallo AM, et al. Sustained phenorypic correction of murine hemophilia A by in vivo gene therapy. Blood 1998; 91: 3273-3281.
110. Connelly S, Andrews JL, Gallo-Penn AM, et al. Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice. Thromb Haemost 1999; 81: 234-239.
111. Gallo-Penn AM, Shirley PS, Andrews JL, et al. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice. Hum Gene Ther 1999; 10: 1791-1802.
112. Tinlin S, Webster S, Giles AR. The development of homologous (canine/anti-canine) antibodies in dogs with haemophilia A (factor VIII deficiency): a ten-year longitudinal study. Thromb Haemost 1993; 69: 21-24.
113. Sarkar R, Gao GP, Chirmule N, et al. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII. Hum Gene Ther 2000; 11: 881-894.
114. Lipshutz GS, Sarkar R, Flebbe-Rehwaldt L, et al. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero. Proc Natl Acad Sci U S A 1999; 96: 13324-13329.
115. Mitani K, Graham FL, Caskey CT, Kochanek S. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci U S A 1995; 92: 3854-3858.
116. Clemens PR, Kochanek S, Sunada Y, et al. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther 1996; 3: 965-972.
117. Kochanek S, Clemens PR, Mitani K, et al. new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A 1996; 93: 5731-5736.
118. Chen HH, Mack LM, Kelly R, et al. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci U S A 1997; 94: 1645-1650.
119. Parks RJ, Chen L, Anton M, et al. helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996; 93: 13565-13570.
120. Parks RJ, Graham FL. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol 1997; 71: 3293-3298.
121. Morral N, O'Neal W, Rice K, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci U S A 1999; 96: 12816-12821.
122. Kafri T, Morgan D, Krahl T, et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci U S A 1998; 95: 11377-11382.
123. Lieber A, He CY, Kirillova I, Kay MA. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 1996; 70: 8944-8960.
124. Balague C, Zhou J, Dai Y, et al. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 2000; 95: 820-828.
125. Kotin RM. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther 1994; 5: 793-801.
126. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098-8108.
127. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994; 8: 148-154.
128. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
129. Miao CH, Nakai H, Thompson AR, et al. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J Virol 2000; 74: 3793-3803.
130. Gnatenko DV, Saenko EL, Jesty J, et al. Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to haemophilia A gene therapy. Br J Haematol 1999; 104: 27-36.
131. Chao H, Mao L, Bruce AT, Walsh CE. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood 2000; 95: 1594-1599.
132. Burton M, Nakai H, Colosi P, et al. Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc Natl Acad Sci U S A 1999; 96: 12725-12730.
133. Kurachi K, Furukawa M, Yao SN, Kurachi S. Biology of factor IX. Hematol Oncol Clin North Am 1992; 6: 991-997.
134. Liles D, Landen CN, Monroe DM, et al. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. Thromb Haemost 1997; 77: 944-948.
135. Herzog RW, Hagstrom JN, Kung SH, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A 1997; 94: 5804-5809.
136. Anson DS, Hock RA, Austen D, et al. Towards gene therapy for hemophilia B. Mol Biol Med 1987; 4: 11-20.
137. Scharfmann R, Axelrod JH, Verma IM. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci U S A 1991; 88: 4626-4630.
138. Hoeben RC, Migchielsen AA, van der Jagt RC, et al. Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position. J Virol 1991; 65: 904-912.
139. Zhou JM, Qiu XF, Lu DR, et al. Long-term expression of human factor IX cDNA in rabbits. Sci China B 1993; 36: 1333-1341.
140. Chen L, Nelson DM, Zheng Z, Morgan RA. Ex vivo fibroblast transduction in rabbits results in long-term (>600 days) factor IX expression in a small percentage of animals. Hum Gene Ther 1998; 9: 2341-2351.
141. Lu DR, Zhou JM, Zheng B, et al. Stage I clinical trial of gene therapy for hemophilia B. Sci China B 1993; 36: 1342-1351.
142. Qiu X, Lu D, Zhou J, et al. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients. Chin Med J Engl 1996; 109: 832-839.
143. Roman M, Axelrod JH, Dai Y, et al. Circulating human or canine factor IX from retrovirally transduced primary myoblasts and established myoblast cell lines grafted into murine skeletal muscle. Somat Cell Mol Genet 1992; 18: 247-258.
144. Nelson DM, Metzger ME, Donahue RE, Morgan RA. In vivo retrovirus-mediated gene transfer into multiple hematopoietic lineages in rabbits without preconditioning. Hum Gene Ther 1997; 8: 747-754.
145. Armentano D, Thompson AR, Darlington G, Woo SL. Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: potential for gene therapy of hemophilia B. Proc Natl Acad Sci U S A 1990; 87: 6141-6145.
146. Gerrard AJ, Hudson DL, Brownlee GG, Watt FM. Towards gene therapy for haemophilia B using primary human keratinocytes. Nat Genet 1993; 3: 180-183.
147. Gerrard AJ, Austen DE, Brownlee GGRecombinantfactor. IX secreted by transduced human keratinocytes is biologically active. Br J Haematol 1996; 95: 561-563.
148. Lozier JN, Yankaskas JR, Ramsey WJ, et al. Gut epithelial cells as targets for gene therapy of hemophilia. Hum Gene Ther 1997; 8: 1481-1490.
149. Brauker JH, Carr Brendel VE, Martinson LA, et al. Neovascularization of synthetic membranes directed by membrane microarchitecture. J Biomed Mater Res 1995; 29: 1517-1524.
150. Carr Brendel VE, Geller RL, Thomas TJ, et al. Transplantation of cells in an immunoisolation device for gene therapy. Methods Mol Biol 1997; 63: 373-387.
151. Hortelano G, Xu N, Vandenberg A, et al. Persistent delivery of factor IX in mice: gene therapy for hemophilia using implantable microcapsules. Hum Gene Ther 1999; 10: 1281-1288.
152. Kay MA, Landen CN, Rothenberg SR, et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci U S A 1994; 91: 2353-2357.
153. Smith TA, Mehaffey MG, Kayda DB, et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-402.
154. Kung SH, Hagstrom JN, Cass D, et al. Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood 1998; 91: 784-790.
155. Dai Y, Schwarz EM, Gu D, et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 1995; 92: 1401-1405.
156. Fields PA, Kowalczyk DW, Arruda VR, et al. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther 2000; 1: 225-235.
157. Lozier JN, Metzger ME, Donahue RE, Morgan RA. The rhesus macaque as an animal model for hemophilia B gene therapy. Blood 1999; 93: 1875-1881.
158. Schneider H, Adebakin S, Themis M, et al. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B. J Gene Med 1999; 1: 424-432.
159. Fang B, Eisensmith RC, Wang H, et al. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995; 6: 1039-1044.
160. Smith TA, White BD, Gardner JM, et al. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther 1996; 3: 496-502.
161. Fang B, Wang H, Gordon G, et al. Lack of persistence of E1-recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther 1996; 3: 217-222.
162. Koeberl DD, Alexander IE, Halbert CL, et al. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci U S A 1997; 94: 1426-1431.
163. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors [see Comments]. Nat Med 1999; 5: 64-70.
164. Nakai H, Iwaki Y, Kay MA, Couto LB. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol 1999; 73: 5438-5447.
165. Wang L, Takabe K, Bidlingmaier SM, et al. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci U S A 1999; 96: 3906-3910.
166. Wang L, Nichols TC, Read MS, et al. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther 2000; 1: 154-158.
167. Hagstrom JN, Couto LB, Scallan C, et al. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter. Blood 2000; 95: 2536-2542.
168. Monahan PE, Samulski RJ, Tazelaar J, et al. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 1998; 5: 40-49.
169. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector [see Comments]. Nat Med 1999; 5: 56-63.
170. Chao H, Samulski R, Bellinger D, et al. Persistent expression of canine factor IX in hemophilia B canines. Gene Ther 1999; 6: 1695-1704.
171. Young SM Jr, Xiao W, Samulski RJ. Site-specific targeting of DNA plasmids to chromosome 19 using AAV cis and trans sequences. Methods Mol Biol 2000; 133: 111-126.
172. Yant SR, Meuse L, Chiu W, et al. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 2000; 25: 35-41.
173. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10: 1735-1737.
174. Miao CH, Ohashi K, Patijn GA, et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro [in process citation]. Mol Ther 2000; 1: 522-532.
175. Kren BT, Parashar B, Bandyopadhyay P, et al. Correction of the UDP-glucuronosyltransferase gene defect in the Gunn rat model of Crigler-Najjar syndrome type I with a chimeric oligonucleotide. Proc Natl Acad Sci U S A 1999; 96: 10349-10354.
176. Kren BT, Bandyopadhyay P, Steer CJ. In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides [see Comments]. Nat Med 1998; 4: 285-290.
177. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector [see Comments]. Nat Genet 2000; 24: 257-261.
178. Zhang WW, Josephs SF, Zhou J, et al. Development and application of a minimal-adenoviral vector system for gene therapy of hemophilia A. Thromb Haemost 1999; 82: 562-571.
179. Cameron C, Notley C, Hoyle S, et al. The canine factor VIII cDNA and 5′ flanking sequence. Thromb Haemost 1998; 79: 317-322.
180. Matzinger P. An innate sense of danger. Semin Immunol 1998; 10: 399-415.